BR9800641A - Construção de ácido nucléico para a expressão regulada pelo ciclo celular de genes estruturais. - Google Patents
Construção de ácido nucléico para a expressão regulada pelo ciclo celular de genes estruturais.Info
- Publication number
- BR9800641A BR9800641A BR9800641-0A BR9800641A BR9800641A BR 9800641 A BR9800641 A BR 9800641A BR 9800641 A BR9800641 A BR 9800641A BR 9800641 A BR9800641 A BR 9800641A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- cell cycle
- structural genes
- regulated expression
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
Abstract
Patente de Invenção:<B>"CONSTRUçãO DE AçIDO NUCLéICO PARA A EXPRESSãO REGULADA PELO CICLO CELULAR DE GENES ESTRUTURAIS"<D>. A invenção refere-se à uma construção de ácido nucléico compreendendo pelo menos uma seq³ência ativadora, pelo menos um módulo promotor quimérico compreendendo uma seq³ência de nucleotídeos, a qual liga uma proteína da família de E2F e uma proteína da família de CDF-1, e pelo menos um gene estrutural, onde o dito módulo promotor quimérico causa uma regulação completa da expressão do gene no ciclo celular mais tarde do que o promotor B-myb, porém mais cedo do que o promotor cdc25C, e à proteína CDF-1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97102547A EP0860445A1 (en) | 1997-02-18 | 1997-02-18 | New nucleotide sequences for the cell cycle regulated expression of structural genes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9800641A true BR9800641A (pt) | 1999-12-07 |
Family
ID=8226488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9800641-0A BR9800641A (pt) | 1997-02-18 | 1998-02-17 | Construção de ácido nucléico para a expressão regulada pelo ciclo celular de genes estruturais. |
Country Status (13)
Country | Link |
---|---|
US (1) | US6380170B1 (pt) |
EP (1) | EP0860445A1 (pt) |
JP (1) | JPH10229888A (pt) |
KR (1) | KR19980071443A (pt) |
CN (1) | CN1197077A (pt) |
AR (1) | AR011446A1 (pt) |
AU (1) | AU735514B2 (pt) |
BR (1) | BR9800641A (pt) |
CA (1) | CA2224123A1 (pt) |
CZ (1) | CZ46098A3 (pt) |
HU (1) | HUP9800329A3 (pt) |
PL (1) | PL324919A1 (pt) |
TR (1) | TR199800237A2 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9724829D0 (en) * | 1997-11-21 | 1998-01-21 | Muller Rolf | Transcription factor |
CZ121599A3 (cs) | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
CN1780920B (zh) * | 2003-05-12 | 2012-03-28 | 波多玛克制药有限公司 | 基因表达抑制剂 |
WO2005033284A2 (en) * | 2003-10-01 | 2005-04-14 | The Regents Of The University Of California | Compositions and methods for gene expression |
WO2005085455A1 (en) * | 2004-03-09 | 2005-09-15 | Kam Man Hui | Compositions and methods for treating disease |
EP2298815B1 (en) * | 2005-07-25 | 2015-03-11 | Emergent Product Development Seattle, LLC | B-cell reduction using CD37-specific and CD20-specific binding molecules |
WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
EP2167130A2 (en) * | 2007-07-06 | 2010-03-31 | Trubion Pharmaceuticals, Inc. | Binding peptides having a c-terminally disposed specific binding domain |
NZ603059A (en) * | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
SG10202002577XA (en) | 2015-09-21 | 2020-04-29 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2179014C (en) * | 1993-12-17 | 2003-07-29 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
WO1996006938A1 (de) * | 1994-08-26 | 1996-03-07 | Hoechst Aktiengesellschaft | Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
DE19524720A1 (de) | 1995-07-12 | 1997-01-16 | Hoechst Ag | Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3" |
GB9502873D0 (en) * | 1995-02-14 | 1995-04-05 | Medical Res Council | Transcription factor |
FR2735789B1 (fr) * | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
DE19605274A1 (de) | 1996-02-13 | 1997-08-14 | Hoechst Ag | Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln |
DE19605279A1 (de) | 1996-02-13 | 1997-08-14 | Hoechst Ag | Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung |
-
1997
- 1997-02-18 EP EP97102547A patent/EP0860445A1/en not_active Withdrawn
-
1998
- 1998-02-16 TR TR1998/00237A patent/TR199800237A2/xx unknown
- 1998-02-16 AR ARP980100683A patent/AR011446A1/es unknown
- 1998-02-16 AU AU55398/98A patent/AU735514B2/en not_active Ceased
- 1998-02-16 CZ CZ98460A patent/CZ46098A3/cs unknown
- 1998-02-17 CN CN98106925A patent/CN1197077A/zh active Pending
- 1998-02-17 BR BR9800641-0A patent/BR9800641A/pt not_active IP Right Cessation
- 1998-02-17 HU HU9800329A patent/HUP9800329A3/hu unknown
- 1998-02-18 US US09/025,343 patent/US6380170B1/en not_active Expired - Fee Related
- 1998-02-18 PL PL98324919A patent/PL324919A1/xx not_active Application Discontinuation
- 1998-02-18 KR KR1019980004878A patent/KR19980071443A/ko not_active Application Discontinuation
- 1998-02-18 JP JP10036408A patent/JPH10229888A/ja active Pending
- 1998-02-18 CA CA002224123A patent/CA2224123A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HU9800329D0 (en) | 1998-04-28 |
CA2224123A1 (en) | 1998-08-18 |
AU5539898A (en) | 1998-08-20 |
JPH10229888A (ja) | 1998-09-02 |
HUP9800329A3 (en) | 2001-10-29 |
AU735514B2 (en) | 2001-07-12 |
EP0860445A1 (en) | 1998-08-26 |
PL324919A1 (en) | 1998-08-31 |
AR011446A1 (es) | 2000-08-16 |
HUP9800329A2 (hu) | 1998-09-28 |
CZ46098A3 (cs) | 1998-09-16 |
TR199800237A2 (xx) | 1998-09-21 |
CN1197077A (zh) | 1998-10-28 |
US6380170B1 (en) | 2002-04-30 |
KR19980071443A (ko) | 1998-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9800641A (pt) | Construção de ácido nucléico para a expressão regulada pelo ciclo celular de genes estruturais. | |
D’Souza et al. | Mitochondrial transcription and translation: overview | |
Edwalds-Gilbert et al. | Regulation of poly (A) site use during mouse B-cell development involves a change in the binding of a general polyadenylation factor in a B-cell stage-specific manner | |
Debyser et al. | Coordination of leading and lagging strand DNA synthesis at the replication fork of bacteriophage T7 | |
Watanabe | Unique features of animal mitochondrial translation systems–The non-universal genetic code, unusual features of the translational apparatus and their relevance to human mitochondrial diseases– | |
BR9807886A (pt) | Processo para se obter uma planta com caracterìsticas de crescimento alteradas ou arquitetura alterada, gene quimérico, célula de planta, planta, semente da mesma, fragmento isolado de dna, e, usos de uma proteìna que controla a divisão celular, e de um dna que codifica a mesma | |
BR9712077A (pt) | Expressão de proteìnas de alto nìvel | |
BR9803346A (pt) | Microorganismos e processo para a preparação fermentativa del-cisteìna, l-cistina, n-acetil-serina ou derivados de tiazoldina. | |
BR0313202A (pt) | Formas adicionais para interferir com as moléculas de rna | |
FR2631974B1 (fr) | Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes | |
Poldermans et al. | Studies on the function of two adjacent N6, N6-dimethyladenosines near the 3'end of 16 S ribosomal RNA of Escherichia coli. II. The effect of the absence of the methyl groups on initiation of protein biosynthesis. | |
ATE211174T1 (de) | Thymidin-kinase-mutanten | |
BR9803982A (pt) | Polietilenoiminas de baixo peso molecular, toleráveis biologicamente. | |
Matsuda et al. | Identification of the functional domains of the transcriptional regulator CRE-BP1. | |
BR9811865A (pt) | Isolamento de um novo gene de fator de senescência, p23 | |
ATE350472T1 (de) | Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen | |
ATE171212T1 (de) | Corticotropin freisetzende rezeptoren des faktor 2 | |
CA2169631A1 (en) | A novel homeobox factor which stimulates insulin expression in pancreatic islet cells | |
DE69535789D1 (de) | Il-2r-assoziiertes polypeptid und dafür kodierende dna-molekülen | |
ATE364087T1 (de) | Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren | |
Ejiri et al. | Characterization of an Additional Factor for Amino Acid Polymerization from Silk Glands of Silkwarms | |
Randerath et al. | Specific lack of the hypermodified nucleoside, queuosine, in hepatoma mitochondrial aspartate transfer RNA and its possible biological significance | |
BR9811853A (pt) | Processos para aumentar o rendimento em plantas | |
Watanabe et al. | Primary sequence of mitochondrial tRNAArg of a nematode Ascaris suum: occurrence of unmodified adenosine at the first position of the anticodon | |
BR9800882A (pt) | Processos de transcrição in vitro para a separação de produtos naturais e outras substâncias químicas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer |
Free format text: AVENTIS PHARMA DEUTSCHLAND GMBH (DE) |
|
HHT | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Free format text: REFERENTE A RPI 1577 DE 20010327 - ITEM (71) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A,8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1894 DE 24/04/2007. |